These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 26289787)

  • 1. Early investigational drugs targeting tau protein for the treatment of Alzheimer's disease.
    Anand K; Sabbagh M
    Expert Opin Investig Drugs; 2015; 24(10):1355-60. PubMed ID: 26289787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs in Alzheimer's disease: current progress.
    Berk C; Paul G; Sabbagh M
    Expert Opin Investig Drugs; 2014 Jun; 23(6):837-46. PubMed ID: 24702504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments with tau-based drug discovery.
    Iqbal K; Liu F; Gong CX
    Expert Opin Drug Discov; 2018 May; 13(5):399-410. PubMed ID: 29493301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical to phase II amyloid beta (A
    Parsons CG; Rammes G
    Expert Opin Investig Drugs; 2017 May; 26(5):579-592. PubMed ID: 28362514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau therapeutics for Alzheimer's disease: the promise and the challenges.
    Gold M
    J Mol Neurosci; 2002 Dec; 19(3):331-4. PubMed ID: 12540060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why do trials for Alzheimer's disease drugs keep failing? A discontinued drug perspective for 2010-2015.
    Mehta D; Jackson R; Paul G; Shi J; Sabbagh M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):735-739. PubMed ID: 28460541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tau immunotherapies for Alzheimer's disease.
    Hoskin JL; Sabbagh MN; Al-Hasan Y; Decourt B
    Expert Opin Investig Drugs; 2019 Jun; 28(6):545-554. PubMed ID: 31094578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
    Khan A; Corbett A; Ballard C
    Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.
    Prickaerts J; Heckman PRA; Blokland A
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1033-1048. PubMed ID: 28772081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.
    Wicke K; Haupt A; Bespalov A
    Expert Opin Investig Drugs; 2015; 24(12):1515-28. PubMed ID: 26548316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alzheimer's Disease Drug Discovery--11th International Conference--Targeting Pathological Tau. 27-28 September 2010, Jersey City, NJ, USA.
    Wolfe MS
    IDrugs; 2010 Dec; 13(12):828-9. PubMed ID: 21154135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical, phase I, and phase II investigational clinical trials for treatment of progressive supranuclear palsy.
    Shoeibi A; Olfati N; Litvan I
    Expert Opin Investig Drugs; 2018 Apr; 27(4):349-361. PubMed ID: 29602288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Zecca C; Barulli MR; Bellomo A; Pilotto A; Daniele A; Greco A; Logroscino G
    Biomed Res Int; 2016; 2016():3245935. PubMed ID: 27429978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future targeted disease modifying drugs for Alzheimer's disease.
    Dash SK
    Recent Pat CNS Drug Discov; 2011 Jan; 6(1):65-76. PubMed ID: 21073430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based therapy in Alzheimer's disease.
    Pul R; Dodel R; Stangel M
    Expert Opin Biol Ther; 2011 Mar; 11(3):343-57. PubMed ID: 21261567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel disease-modifying therapies for Alzheimer's disease.
    Jiang T; Yu JT; Tan L
    J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current perspectives on pharmacotherapy of Alzheimer's disease.
    Chopra K; Misra S; Kuhad A
    Expert Opin Pharmacother; 2011 Feb; 12(3):335-50. PubMed ID: 21222549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau-based therapies in neurodegeneration: opportunities and challenges.
    Li C; Götz J
    Nat Rev Drug Discov; 2017 Dec; 16(12):863-883. PubMed ID: 28983098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Lozupone M; Santamato A; Tortelli R; Galizia I; Prete C; Daniele A; Pilotto A; Greco A; Logroscino G
    Immunotherapy; 2016 Sep; 8(9):1119-34. PubMed ID: 27485083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.